
Humana (HUM) Stock Forecast & Price Target
Humana (HUM) Analyst Ratings
Bulls say
Humana's strong financial outlook is underscored by the upward revision of its 2025 earnings per share (EPS) estimate to $17.06, reflecting positive second-quarter results and adjusted guidance. The company anticipates year-over-year earnings growth for 2027, driven by effective margin initiatives, highlighting its ability to navigate the competitive landscape in government-sponsored healthcare programs. Additionally, Humana's strong performance in Medicare Advantage star ratings strengthens its market position, providing a competitive advantage amidst changing regulatory and reimbursement environments.
Bears say
Humana is facing a challenging outlook with expectations of a slight decline in earnings per share (EPS) for 2026 compared to 2025, primarily influenced by headwinds related to the Medicare Star ratings. Key downside risks include increased competition in Medicare Advantage (MA), lower reimbursement rates, and a decrease in individual prescription drug plan (PDP) membership, all potentially impacting overall growth in healthcare services. Additionally, the management acknowledges that increased investments may be necessary to support the recovery of Star ratings, which could further strain future earnings projections.
This aggregate rating is based on analysts' research of Humana and is not a guaranteed prediction by Public.com or investment advice.
Humana (HUM) Analyst Forecast & Price Prediction
Start investing in Humana (HUM)
Order type
Buy in
Order amount
Est. shares
0 shares